This distinguishes it from better-known compounds such as semaglutide (Ozempic/Wegovy), which targets only the GLP-1 receptor, and from tirzepatide (Mounjaro/Zepbound), which is a dual GLP-1/GIP agonist
BPC-157/TB-500 10+10mg $160.00 Volume discounts Auto-applied at checkout Free shipping on orders of $200+ Compound Identity COMPOUND NAME BPC-157 and TB-500 peptide blend SYNONYMS Body Protection Compound-157 (BPC-157), Thymosin Beta-4 Fragment (TB-500) CAS NUMBER BPC-157: 137525-51-0 TB-500: 77591-33-4 MOLECULAR FORMULA BPC-157: C 62 H 98 N 16 O 22 TB-500: C 212 H 350 N 56 O 78 S MOLECULAR WEIGHT BPC-157: 1419.53552 g/mol TB-500: ~4963.49 g/mol STRUCTURE Synthetic tetrapeptide PEPTIDE SEQUENCE BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val TB-500: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Lys-Asp-Lys-Ser-Ile-Lys-Asn-Asp-Lys-Pro-Thr CHEMICAL STRUCTURE BPC-157: TB-500: CHEMICAL STRUCTURE BPC-157: C 62 H 98 N 16 O 22 TB-500: C 212 H 350 N 56 O 78 S Mechanism of Action BPC-157 is believed to act via modulation of nitric oxide pathways, angiogenesis induction, and cytoprotective effects through VEGFR-2 and FAK-paxillin pathways
The injections can serve as a powerful jumpstart that provides the energy, motivation, and metabolic support needed to establish new routines
FOXO4-DRI is a synthetic senolytic peptide developed to selectively target and eliminate senescent cells, often referred to as "zombie cells." These dysfunctional cells accumulate with aging and are associated with chronic inflammation, tissue degeneration, and age-related decline
